Medical use of cannabis for glaucoma

(October 2018)

Background

The clinical utility of cannabis (sometimes referred to as marijuana or marihuana) for the treatment of glaucoma is limited by the inability to separate the potential clinical action from the undesirable neuropsychological and behavioural effects. The Canadian Ophthalmological Society does not support the medical use of cannabis for the treatment of glaucoma due to the short duration of action, the incidence of undesirable psychotropic and other systemic side effects and the absence of scientific evidence showing a beneficial effect on the course of the disease. This is in contrast to other more effective and less harmful medical, laser and surgical modalities for the treatment of glaucoma.

Access Details

Read the full policy statement from the Canadian Ophthalmological Society (COS) and the Canadian Glaucoma Society (CGS).

Related Resources

So You Got a Complaint – Now What?!

Articles Patients’ complaints involving ophthalmologists in the province of Ontario,...

More Info

Immediate Sequential Bilateral Cataract Surgery (ISBCS) COVID-19 Considerations

Updated March, 2021 This document, which is subject to regular...

More Info

COVID-19 Vaccination Tool Kit for Health Care Providers

The current edition of the tool kit includes information on...

More Info

Why Do My Eyes Burn When I Cry? Causes and Treatments healthline.com/health/eye-hea… via @Healthline

About 3 hours ago from Can Ophthal Society's Twitter via Twitter for Android

Can Ophthal Society's Twitter via Twitter Web Client